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Introduction
Population-based cancer registration plays a key role in malig-
nant disease surveillance by providing data needed to calculate
incidence, survival, cancer cluster investigations and prevalence
trends. The Finnish Cancer Registry (FCR) maintains a national
register of all cancer cases diagnosed in Finland and conducts
epidemiological and statistical research on cancer [1].
The four main dimensions of cancer registry quality evalu-
ation are validity, timeliness, comparability and complete-
ness. Completeness is used to express the extent to which
all incident cancers occurring in the population are included
in the registry database [2]. Cancer registry data are utilized
widely in cancer research and poor completeness of data
introduces bias to incidence and survival estimates [3].
Rare diseases, such as childhood cancers, are sensitive to
the effects of incomplete and/or inaccurate registration.
Childhood cancer incidence has been reported to be higher
in the Nordic countries compared to the rest of Europe [4].
This is thought to be explained by high completeness of the
registers, as notification of new cancer cases is mandatory in
all Nordic countries [5], and the Nordic cancer registries are
reported to have close to 100% completeness for solid
malignancies [6–10]. The survival rate of certain childhood
cancer types (brain, lymphoma and acute lymphoblastic leu-
kemia) in Finland was recently reported to be among the
highest in the world [11].
The validity, comparability, timeliness and completeness
of the FCR for the period of 2009–2013 have been previously
described [6]. Completeness for all cancers was evaluated at
95% but the estimate for childhood cancers was, however,
lower at 80%.
The aim of our study was to address possible data quality
issues. The completeness of childhood cancer registration in
the FCR in 2009–2013 was studied by tracing back poten-
tially missed cases recognized by an independent data
source. We explored completeness based on the cancer type
and possible reasons underlying suboptimal completeness.
Material and methods
The FCR compiles data on all incident cancers in Finland
(since 1953). Health care providers have a statutory
obligation to notify new cancer cases or strong cancer suspi-
cions to the registry. Cancers reported to the FCR have been
coded according to the ICD-O-3 [12] since the year 2007 and
childhood cancer cases include an International Classification
of Childhood Cancer (ICCC-3) [13] diagnosis code. The FCR
has three independent information sources: clinical cancer
notifications from hospitals, notifications from pathology lab-
oratories and cause of death data received from Statistics
Finland [1]. Due to mandatory reporting, cumulating informa-
tion and active manual work in reviewing it, FCR data is of
high quality [6].
The Care Register for Health Care (HILMO) contains data
on all inpatient care episodes in health care centers and hos-
pitals, and on all outpatient visits in public hospitals in
Finland [14]. Completeness of HILMO has been estimated to
be up to 95%. However, due to the administrative and cross-
sectional nature of the data, the positive predictive value
(proportion of cases confirmed as true positives) varies
greatly, being lowest for rare diagnoses [15].
We used the independent case-ascertainment method
[16] to assess completeness of the FCR by comparing FCR
and HILMO data and verified the validity of the potentially
missing cases by reviewing patient medical records (see
below).
From the FCR, we extracted all childhood cancer cases (all
malignant cases and all tumors of the central nervous system
regardless of their malignancy) diagnosed at the age of 0–14
years in 2009–2013. We excluded basal cell carcinomas of
the skin and classified neoplasms into non-solid tumors
(hematological malignancies, ICD-O-3 morphology codes
9590) and solid tumors (all other malignancies) as previ-
ously described [6].
From HILMO, we identified all care episodes or visits in
2009–2013 with the following ICD-10 diagnoses: all ‘C’ codes
excluding C44 basal cell carcinomas of the skin, D32-D33,
D41-D43 and D45-D47. We chose the earliest date of hospi-
talization or outpatient visit with a relevant diagnosis under
the age of 15 years. We then categorized the ICD-10-diagno-
ses as non-solid tumors (C81-C96 and D45-D47) and solid
tumors (all the remaining) [6].
Solid tumors reported by HILMO were linked to the solid
tumors found in the FCR using the unique personal identity
code given to all residents of Finland. The same linkage was
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performed for non-solid tumors. Cases in HILMO that could
not be matched to cases in the FCR were considered poten-
tially missed cases.
We requested patient information on all potentially
missed cases from all university hospitals responsible for
treating childhood cancer (Helsinki, Tampere, Turku, Kuopio
and Oulu) using a structured enquiry form. Data on patients
whose information could not be retrieved from university
hospitals were inquired from patient file archives of smaller
hospitals. Second, for all potentially missed cases, the notifi-
cation and coding history at the FCR was manually reviewed.
Completeness estimates with 95% binomial confidence
intervals were derived from the number of cases recorded in
the FCR divided by the total number of cases (i.e., sum of
cases recorded in the FCR and cases confirmed as missing
from the FCR). We calculated completeness for all childhood
cancer sites combined, for solid and non-solid tumors, for all
12 ICCC-3 main groups and for three age groups.
Results
In the period 2009–2013, the FCR comprised a total of 741
incident childhood cancer cases. Of these, 441 were solid
and 300 were non-solid cancers. A total of 1072 childhood
cancer cases were retrieved from HILMO in 2009–2013 and
157 of these patients could not be matched to cases in
the FCR.
Table 1 shows information on all 157 potentially missed
cases after assessment of the patients’ medical records. In all,
94 patients had an erroneous cancer diagnosis in HILMO. We
confirmed 49 cases as true cancer patients that had not
been notified to the FCR.
The highest proportions of incorrect cancer diagnoses in
the group of potentially missed cases were present in ICCC-3
groups I (leukemia), II (lymphoma) and XI (malignant epithe-
lial tumors); the proportions being 33 out of 43, 9 out of 9
and 11 out of 13 cases, respectively (Supplementary
material).
Correcting the FCR data for 2009–2013 by adding the
missing cases increased the total number of childhood can-
cer cases by 7% (from 741 to 790 cases).
Completeness of the FCR
After confirmation of the 49 missing cases, completeness of
the FCR was estimated at 94% (95% CI 92–95%) for all child-
hood cancer sites, 92% (95% CI 89–94%) for solid tumors
and 97% (95% CI 94–98%) for non-solid tumors (Table 2).
Lymphomas, renal cancers and hepatic cancers showed
100% completeness. Lowest completeness was observed for
central nervous system (CNS) tumors, retinoblastoma, bone
cancers and other and unspecified malignant neoplasms
(ICCC-3 group XII). Completeness of retinoblastoma was
extremely low at only 55% (95% CI 36–72%), while all other
cancers coherently showed completeness above 85%
(Table 2).
We identified a slight, non-significant (p¼.16) trend of
increasing completeness with advancing patient age
(Supplementary material).
Table 1. Classification of the potentially missed cases after reviewing patient
medical records.
Incorrect cancer diagnoses in HILMO 94
Incorrect ICD-10 code reported to HILMO; correct diagnosis
identified from the FCR
25
Non-registrable neoplasm or disease such as a cyst or infection 23
Benign tumor (outside the CNS)a 13
Benign blood disease 9
Typographical error 9
Malignancy not verified 4
Benign intracranial endocrine tumorb 4
Other or unknown reason 7
Excluded cases 14
Invalid personal identity code in the HILMO, patient could not be
identified
7
Incorrect classification in the FCR databasec 5
Not Finnish by nationality 1
Patient information not found in the hospital of supposed treatment
or in any of the patient file archives
1
Childhood cancer cases confirmed as missing from the FCR 49
Total 157
aBenign and borderline tumors of the CNS are registered in the FCR.
bBenign intracranial endocrine tumors i.e., tumors of pituitary gland, cranio-
pharyngeal duct and pineal gland are not included in CNS tumors, and thus,
are not registered in the FCR.
cSome ICD-O-3 codes had been incorrectly classified as solid or non-solid can-
cers in the FCR data and these cases had been incorrectly labeled as missing.
Table 2. Completeness of childhood cancer (diagnostic age 0–14 years) registration in the Finnish Cancer Registry (FCR) and corrected number of childhood
cancer cases, 2009–2013.









Total non-solid tumors 300 10 310 96.8% (94.1, 98.4)
I Leukemias, myeloproliferative diseases and myelodysplastic diseases 243 10 253 95.7% (92.9, 98.1)
II Lymphomas and reticuloendothelial neoplasms 57 – 57 100% (93.7, 100%)
Total solid tumors 441 39 480 91.9% (89.1, 94.2)
III CNS and miscellaneous intracranial and intraspinal neoplasms 198 15 213 93.0% (88.7, 96.0)
IV Neuroblastoma and other peripheral nervous cell tumors 40 1 41 97.6% (87.1, 99.9)
V Retinoblastoma 18 15 33 54.5% (36.4, 71.9)
VI Renal tumors 41 – 41 100% (91.4, 100%)
VII Hepatic tumors 9 – 9 100% (66.4, 100%)
VIII Malignant bone tumors 19 2 21 90.5% (69.6, 98.8)
IX Soft tissue and other extraosseous sarcomas 45 2 47 95.9% (85.5, 99.5)
X Germ cell tumors, trophoblastic tumors, and neoplasm of gonads 18 1 19 94.7% (74.0, 99.9)
XI Other malignant epithelial neoplasms and malignant melanomas 47 2 49 95.9% (86.0, 99.5)
XII Other and unspecified malignant neoplasms 6 1 7 85.7% (42.1, 99.6)
Total all tumors 741 49 790 93.8% (91.9, 95.4)
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Discussion
We found the FCR to have high coverage (94%) of childhood
cancers in 2009–2013, significantly higher than the previous
estimate of 80% [6]. The completeness estimate for child-
hood cancers still remained slightly lower than the previous
completeness estimate for all ages (95%).
In the independent case-ascertainment method, registry
data are compared to data from another, independently
compiled registry source [16]. In administrative registries
such as HILMO, however, erroneous diagnoses are common
[15,17] and administrative claims provide only a robust tool
to determine the extent of missing registry data [18].
When using unvalidated hospital discharge data for can-
cer research and incidence statistics, the number of false
positive cancer diagnoses warrant caution. Leukemias, lym-
phomas and epithelial neoplasms had a high proportion of
false positive cancer diagnoses in HILMO; benign abnormal-
ities of blood, benign lymphadenopathy and benign skin
tumors are common clinical findings occasionally incorrectly
registered to HILMO with a malignant ICD-10 code. It has
previously been reported that more than half of myelodys-
plastic syndrome or myeloproliferative neoplasm cases
retrieved from HILMO were missing from the FCR [19]. We,
however, observed that among childhood patients, 75% of
the myelodysplastic syndrome or myeloproliferative neo-
plasm cases potentially missing from the FCR were, in fact,
false positive cancer diagnoses in HILMO.
Completeness
Our evaluation supports high completeness of childhood
cancer registration in the FCR at 94% for all sites, with 92%
for solid cancers and 97% for non-solid cancers.
Completeness was lowest for CNS tumors, retinoblastoma,
bone cancers and unspecified cancers. Completeness was
highest for lymphomas, renal cancers and hepatic cancers.
However, results concerning bone, hepatic and unspecified
cancers were based on small numbers.
The quality of childhood cancer registration has not been
widely studied and published reports have focused on pedi-
atric cancer registries [20–25]. Pediatric cancer registries
often operate closely with pediatric oncology clinics and
their data sources may differ from those of population-based
national cancer registries such as the FCR [26]. Completeness
of the Swiss Childhood Cancer Registry has been estimated
at >95% and lowest completeness was reported in tumors
of digestive organs, endocrine glands and the brain [21]. In
Britain, completeness of childhood cancer registration in gen-
eral British cancer registries has been estimated at 92–96%.
Registration of retinoblastoma was poor in the general regis-
tries but complete in the National Registry of Childhood
Tumors [22]. Completeness of childhood leukemia registra-
tion in the Dutch Leukemia Study Group and in the Dutch
Cancer Registry has been estimated at 96.9% and 95.5%,
respectively [23].
We could indicate missing cancer notifications in tumors
lacking histological verification such as cancers of the eye
and tumors of the CNS. Retinoblastoma patients comprised
over one-third of the cases missing from the FCR. When
diagnosing retinoblastoma, biopsies are contraindicated [27]
and eye enucleation as treatment (allowing for a patho-
logical sample) is rarely performed [28]. Both childhood and
adulthood CNS tumor registration in the FCR is incomplete
[6]. The childhood CNS tumors confirmed as missing from
the FCR were mainly nonmalignant or had neither been
biopsied nor surgically removed (i.e., no pathological notifica-
tion was available).
For cases missing from the FCR (other than retinoblasto-
mas and CNS tumors), common traits were long diagnostic
processes and rare diagnoses. A cancer notification should
always be made to the FCR when a conclusive diagnosis is
reached. We also identified three individuals diagnosed
abroad who had not been notified to the FCR despite return-
ing to Finland.
Previously, completeness of childhood cancer registration
in the FCR was estimated at 80%, with 179 persons diag-
nosed with childhood cancer registered to HILMO but not to
the FCR, compared to the 157 cases potentially missing in
this study [6]. After reviewing the linkage process, we found
that 22 patients had been misclassified as adults in the previ-
ous report due to uncertainty related to the time of
diagnosis.
Moving forward
As of 2020, the FCR will no longer accept clinical cancer noti-
fications on paper. The FCR now provides a new web-based
notification system for cancer reporting. The required data
fields have been minimized in order to motivate reporting.
The FCR has contacted the units with systematic low
reporting and they have internally discussed possible under-
lying reasons.
Registration of cancers with no pathological samples, and
therefore, no notifications from pathology laboratories relies
on clinical cancer notifications. Oncologic units are well
informed on when to send cancer notifications to the FCR;
special attention will be targeted toward non-oncologic units
treating these neoplasms such as ophthalmological and
neurosurgical units.
Our study led to the observation that intraocular cancer
reporting in the main treating unit had failed due to tech-
nical errors and the notification procedure has been cor-
rected. Regarding CNS tumors, we have reformulated the
guidance and sampling processes in the pathology laborato-
ries to include all benign neoplasms of the CNS.
Based on the findings of our study, the FCR will imple-
ment a completeness evaluation process using HILMO for
identifying potentially missing cases in the registry routine.
Conclusion
The FCR yields high-quality data for childhood cancer. The
completeness of childhood cancer registration was estimated
at 94%. Compared to cancer in adulthood, completeness of
childhood cancer registration lags behind, calling for
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attention to quality control measures in this subgroup of
rare tumors. Disseminating results on data quality is needed
to increase awareness of the need for clinical cancer
notifications.
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